A trial to evaluate whether encorafenib in combination with binimetinib is effective and safe in participants with high risk Stage II BRAF-mutated melanoma
A trial to evaluate whether encorafenib in combination with binimetinib is effective and safe in participants with high risk Stage II BRAF-mutated melanoma
Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.
Brief summary
The COLUMBUS-AD is a Phase III clinical trial designed to evaluate how effective and safe a BRAF/MEK inhibitor combination therapy is at preventing melanoma returning (local relapse) or spreading to a distant area (metastasis) in comparison to placebo. The trial addresses to patients with high-risk stage II (IIB/IIC) BRAF V600E/K melanoma soon after their tumors are completely removed by surgery.
The BRAF inhibitor that will be used in the study is called encorafenib, and the MEK inhibitor is called binimetinib.
Find out where the clinical trial is conducted
Contact us
Need more information or are interested in enrolling in this study, click on the button to have access to the contact form.
Access to Lay Protocol Synopsis
Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé.